New Data Review: Can treating molecular residual disease (MRD) in colorectal cancer improve outcomes?

In recent years, the detection of molecular residual disease (MRD) by circulating tumor DNA (ctDNA) has emerged as a key part of physician-patient shared decision-making. To date, Natera’s ctDNA MRD assay, Signatera™, has been utilized across tumor types by >40% of US oncologists across >250,000 patients and 1 million timepoints.

The prognostic and predictive value of ctDNA in early-stage colorectal cancer (CRC) has been demonstrated across large scale studies and there is growing data indicating that standard adjuvant therapy remains insufficient for patients with MRD, underscoring a need for more interventional trials.

We will dive into the latest data from publications and ASCO GI, which sheds light on the impact of treatment on MRD.

Updated overall survival (OS) and disease-free survival (DFS) data from the CIRCULATE-JAPAN GALAXY study, a large prospective trial with 2,000+ patients, confirms that ctDNA-positive patients experience worse outcomes than ctDNA-negative patients. Although ctDNA+ patients benefit from adjuvant chemotherapy, more than half still relapse, underscoring the need for new therapies.
The BESPOKE CRC study, the largest multicenter, observational ctDNA study in the US to date, provided insight into how physicians leverage Signatera™ to support treatment decision-making. Results indicated an increase in curative-intent oligometastasis-directed therapy and ctDNA clearance in patients receiving MRD-guided treatment
Other studies are examining the impact of new therapy regimens in the adjuvant setting. Most notably, a retrospective analysis from the CALGB (Alliance)/SWOG 80702 trial demonstrated that ctDNA+ patients treated with celecoxib + chemotherapy achieved significantly improved DFS and OS compared to chemotherapy alone.

Please join us for an insightful webinar and discussion surrounding the management of CRC using MRD testing and the role of ctDNA in enabling new drug development opportunities in early-stage disease.

First name

Last name

Company

Job Title

Country

ZIP/Postal Code

Questions & comments for speakers

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct communication from Endpoints News and/or the sponsor(s). View how we use your data here.

If you are experiencing problems with your registration, please try the Zoom registration page.

ADHAM JURDI

SENIOR MEDICAL DIRECTOR, NATERA

Adham Jurdi, MD, is a Board-certified Medical Oncologist who specializes in gastrointestinal malignancies. Prior to joining Natera, Dr Jurdi practiced at Austin Cancer Center, SUNY Upstate Medical University and the Syracuse VAMC. Throughout his clinical career, he was involved in GI oncology and precision medicine research

Daniel H. Ahn

Oncologist & Professor, Mayo Clinic

Daniel H. Ahn is a GI Medical Oncologist and Professor in the Division of Hematology/Medical Oncology at the Mayo Clinic. Prior to his role at Mayo Clinic, Dr. Ahn completed a fellowship in gastrointestinal oncology at Ohio State University Medical Center and an externship at the National Cancer Institute. He is actively involved in GI oncology research, early therapeutic drug development, and advancing treatment strategies for complex gastrointestinal cancers.

moderator

JOHN SIMMONS

GLOBAL VP BIOPHARMA & ONCOLOGY PARTNERSHIPS, NATERA

John Simmons, PhD currently leads oncology biopharma partnerships at Natera. Before joining Natera, John completed his postdoctoral fellowship at the National Cancer Institute (NCI) and served as Vice President of Translational Medicine at Personal Genome Diagnostics (PGDx). He received his PhD in Tumor Biology from Georgetown University.